CA2031520A1 - Compositions a base de cytochalasine et methodes therapeutiques - Google Patents

Compositions a base de cytochalasine et methodes therapeutiques

Info

Publication number
CA2031520A1
CA2031520A1 CA002031520A CA2031520A CA2031520A1 CA 2031520 A1 CA2031520 A1 CA 2031520A1 CA 002031520 A CA002031520 A CA 002031520A CA 2031520 A CA2031520 A CA 2031520A CA 2031520 A1 CA2031520 A1 CA 2031520A1
Authority
CA
Canada
Prior art keywords
cytochalasin
administration
cytochalasins
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002031520A
Other languages
English (en)
Inventor
Thomas P. Fondy
Dennis Bogyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syracuse University
Original Assignee
Syracuse University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syracuse University filed Critical Syracuse University
Publication of CA2031520A1 publication Critical patent/CA2031520A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002031520A 1989-04-28 1990-04-27 Compositions a base de cytochalasine et methodes therapeutiques Abandoned CA2031520A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34501089A 1989-04-28 1989-04-28
US345,010 1989-04-28

Publications (1)

Publication Number Publication Date
CA2031520A1 true CA2031520A1 (fr) 1990-10-29

Family

ID=23353087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002031520A Abandoned CA2031520A1 (fr) 1989-04-28 1990-04-27 Compositions a base de cytochalasine et methodes therapeutiques

Country Status (4)

Country Link
EP (1) EP0429585A4 (fr)
JP (1) JPH03505744A (fr)
CA (1) CA2031520A1 (fr)
WO (1) WO1990013293A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250563A (en) * 1991-09-25 1993-10-05 Merck & Co., Inc. Inhibitors of HIV protease
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0616530A1 (fr) * 1991-12-09 1994-09-28 Usher, Thomas Clemens Utilisation de cytochalasines pour inhiber la replication virale
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
ATE278397T1 (de) 1997-03-31 2004-10-15 Boston Scient Ltd Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
IL136343A0 (en) * 1997-12-04 2001-05-20 Yissum Res Dev Co Combined chemo-immunotherapy with liposomal drugs and cytokines
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
WO2009069668A1 (fr) * 2007-11-28 2009-06-04 National University Corporation Nagoya University Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation
US11007176B2 (en) 2019-02-19 2021-05-18 Tzu Chi University Use of actin depolymerizing agents for the treatment of anxiety disorders
CN110563634B (zh) * 2019-09-09 2020-12-08 湖南省中医药研究院 吲哚细胞松弛素类化合物及其制备方法和应用
CN111249445B (zh) * 2020-02-27 2022-11-15 广东医科大学 一种细胞松弛素h软胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289077C (fr) * 1984-08-13 1991-09-17 Harry H. Leveen Traitement du cancer a l'aide de la phlorizine et de ses derives
WO1988010259A1 (fr) * 1987-06-19 1988-12-29 Syracuse University Procedes de purification et compositions de cytochalasine

Also Published As

Publication number Publication date
EP0429585A4 (en) 1992-03-25
EP0429585A1 (fr) 1991-06-05
JPH03505744A (ja) 1991-12-12
WO1990013293A1 (fr) 1990-11-15

Similar Documents

Publication Publication Date Title
JP4524071B2 (ja) Ｓｎ−３８脂質複合体及び使用方法
CA2031520A1 (fr) Compositions a base de cytochalasine et methodes therapeutiques
JP3074733B2 (ja) 脂肪乳剤
US20050238706A1 (en) Pharmaceutically active lipid based formulation of SN-38
EP1104297B1 (fr) Compositions pour le traitement de la leucemie lymphocitaire chronique
AU2002246510A1 (en) SN-38 lipid complexes and methods of use
US7105561B2 (en) Use of etodolac for the treatment of prostate cancer
US7029695B2 (en) Therapeutic compositions containing glutathione analogs
JP2011102321A (ja) 配糖体含有リポソーム
CA2503094A1 (fr) Methodes de traitement de la leucemie myeloide aigue
JP2007326877A (ja) グルタチオン類縁体を含有する治療用組成物
WO1988010259A1 (fr) Procedes de purification et compositions de cytochalasine
PT773782E (pt) Derivados terpenoidicos (sarcodictiinas) uteis como agentes antitumor
US5424296A (en) 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
JP2003528908A (ja) Ｄおよびｌエーテル脂質立体異性体およびリポソーム
CN112979541B (zh) 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
JP2002535251A (ja) 癌治療のための新規化合物
Williams et al. The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes
US5312833A (en) Method of inhibiting tumor growth using xanthocillin X dimethylether
JP2003238414A (ja) 医薬組成物
US20030186950A1 (en) Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
EP1278521B1 (fr) Des salicylates n-heterocycliques substitues destines au traitement du cancer
WO2024077358A1 (fr) Procédé d'augmentation de l'activation de cellules immunitaires et/ou de traitement du cancer à l'aide de dibenzoxazépinones.
JP3246670B2 (ja) インターロイキン−２と５’−デオキシ−５−フルオロウリジンとを含有してなる抗癌剤
Wechter et al. Pillsbury Winthrop LLP

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19931027